ClinicalTrials.gg
RecruitingNCT06065436Updated Oct 16, 2026

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

An interventional study of Collagenase Clostridium Histolyticum and Storz Duolith LiSWT in Peyronie Disease and Erectile Dysfunction, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 16, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Penile Induration with a site in United States — 1 open to participants now, 4 under way, none of them phase 3. Penile Induration · United States.

Planned enrollment
7th of 19
60 · median 40
Started
2024
with 1 other
No phase
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
3 of 22
Mayo Clinic

Among the 22 studies in Penile Induration with a site in United States, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 with no phase, and was the 21st registered.

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

Browse Penile Induration studies →

Open to participants now

1 of the 22 studies in Penile Induration with a site in United States is open now.

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Penile Induration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.

03

Conditions studied

  • Peyronie Disease
  • Erectile Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with PD
  • Palpable penile plaque
  • Dorsal, lateral, or dorsolateral penile curvature
  • Penile curvature > 30 degrees and \< 90 degrees as measured using goniometer during objective curvature assessment
  • Non-calcified plaque or grade 1 calcification ("stippling", no shadowing) as determined by penile duplex Doppler ultrasound (PDDU)
  • "Stable PD symptoms' defined as PD symptom duration > 6-months or stable symptoms > 3-months

Exclusion criteria

Exclusion Criteria:

  • Prior intralesional injections or surgery for PD.
  • Severe baseline penile pain.
  • Moderate or severe baseline ED based on IIEF-EF domain.
  • History of low intensity shockwave therapy for sexual dysfunction (ED or PD).
  • Ventral (downward) or ventrolateral penile curvature.
  • Moderate or severe (grade 2/3) plaque calcification as determined by PDDU.
  • Inability to achieve satisfactory erection rigidity at time of baseline curvature assessment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Collagenase Clostridium Histolyticum with Low Intensity Shockwave Therapy

    Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection with low-intensity shockwave therapy (LiSWT).

    Drug: Collagenase Clostridium Histolyticum · Device: Storz Duolith LiSWT

  • Active comparator
    Collagenase Clostridium Histolyticum

    Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection per standard of care.

    Drug: Collagenase Clostridium Histolyticum

Interventions

  • DrugMicrobial CollagenaseStudies of Microbial CollagenaseMicrobial Collagenase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.

    Also known as: Xiaflex

  • DeviceStorz Duolith LiSWT

    Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.

06

What researchers measure

Primary outcomes

  1. Change in symptom bother

    Measured using the validated Peyronie's Disease Questionnaire (PDQ) subdomain symptom bother. Four questions to evaluate pain or discomfort during vaginal intercourse: responses include "not at all bothered", "a little bit bothered" , "moderately bothered", "very bothered", "extremely bothered"

    Time frame: Baseline, 6 weeks

  2. Change in penetrative sexual intercourse

    Measured using self-reported question: "Over the past 4 weeks: When you attempted intercourse, how often were you able to penetrate (enter) your partner?" Responses include "no sexual activity", "almost never or never" , "a few times (less than half the time)", "sometimes (about half the time)", "Most times (more than half the time)", "almost always or always.

    Time frame: Baseline, 6 weeks

  3. Surgical straightening intervention

    Number of subjects to require surgical straightening

    Time frame: 6 weeks

  4. Change in erectile function

    Measured using the International Index of erectile Function

    Time frame: Baseline, 6 weeks

  5. Change in Erectile Function Domain (IIEF-EF)

    Time frame: Baseline, 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Oct 4, 2023
StartActual
Jan 19, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: A•••@mayo.edu · •••6151→D•••@mayo.edu · •••5076. See the current contact
Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mayo Clinic Minnesota · Rochester, United StatesContact A•••@mayo.edu · •••6151→D•••@mayo.edu · •••5076
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Contact Study contact changed: A•••@mayo.edu · •••6151→D•••@mayo.edu · •••5076. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic Minnesota · Rochester, United StatesContact A•••@mayo.edu · •••6151→D•••@mayo.edu · •••5076
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06065436
Lead sponsor
Mayo Clinic
Responsible party
Tobias S. Kohler, MD, MPH (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 4, 2023
Start date
Jan 19, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Carter Day
Contact
Day.Carter@mayo.edu
507-422-5076
Tobias Kohler, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion